237 related articles for article (PubMed ID: 25868485)
21. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
Terasawa T; Nihashi T; Hotta T; Nagai H
J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
[TBL] [Abstract][Full Text] [Related]
23. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Nievelstein RA
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):565-74. PubMed ID: 24281821
[TBL] [Abstract][Full Text] [Related]
25. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
26. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
27. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
Kim SJ; Lee SW
J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis.
Yin Y; Liu X; Yang X; Guo J; Wang Q; Chen L
Spine J; 2018 Dec; 18(12):2323-2332. PubMed ID: 30121323
[TBL] [Abstract][Full Text] [Related]
29. Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.
Procházka V; Klugar M; Bachanova V; Klugarová J; Tučková D; Papajík T
BMJ Open; 2016 Aug; 6(8):e011729. PubMed ID: 27496236
[TBL] [Abstract][Full Text] [Related]
30. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
Pakos EE; Fotopoulos AD; Ioannidis JP
J Nucl Med; 2005 Jun; 46(6):958-63. PubMed ID: 15937306
[TBL] [Abstract][Full Text] [Related]
32. Decisional early interim (18)F-fluoro-2-deoxy-D-glucose positron emission tomography after two cycles of chemotherapy in de novo Hodgkin lymphoma.
Iltis A; Eder V; Blasco H; Colombat P; Sénécal D
Acta Haematol; 2015; 133(2):172-8. PubMed ID: 25301496
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
[TBL] [Abstract][Full Text] [Related]
34. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
35. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
37. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moskowitz CH; Zelenetz A; Schoder H
J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
[TBL] [Abstract][Full Text] [Related]
38. Value of (18)F-FDG PET for Predicting Response to Neoadjuvant Therapy in Rectal Cancer: Systematic Review and Meta-Analysis.
Maffione AM; Marzola MC; Capirci C; Colletti PM; Rubello D
AJR Am J Roentgenol; 2015 Jun; 204(6):1261-8. PubMed ID: 26001237
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
40. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]